ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
企業コードRSLS
会社名ReShape Lifesciences Inc
上場日Oct 06, 2016
最高経営責任者「CEO」Mr. Paul F. Hickey
従業員数17
証券種類Ordinary Share
決算期末Oct 06
本社所在地1001 Calle Amanecer
都市SAN CLEMENTE
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号92673
電話番号19494296680
ウェブサイトhttps://www.reshapelifesciences.com/obalon/
企業コードRSLS
上場日Oct 06, 2016
最高経営責任者「CEO」Mr. Paul F. Hickey
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし